Coverage
-
October 03, 2022
A Delaware federal judge has rebuffed a biotechnology company's bid for a new trial after a jury determined it owed a rival and Massachusetts General Hospital $4.7 million for infringing their genetic testing patents, while agreeing with some of the plaintiffs' requests to boost their award.
2 other articles on this case.
View all »